Patents by Inventor Aaron Novack

Aaron Novack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRIAZOLYL PHENYL BENZENESULFONAMIDES
    Publication number: 20100190762
    Abstract: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: April 2, 2010
    Publication date: July 29, 2010
    Applicant: CHEMOCENTRYX, INC.
    Inventors: Trevor T. Charvat, Cheng Hu, Anita Melikian, Aaron Novack, Andrew M.K. Pennell, Sreenivas Punna, Edward J. Sullivan, Xuefei Tan, William D. Thomas, Solomon Ungashe, Yibin Zeng
  • GPR120 RECEPTOR AGONISTS AND USES THEREOF
    Publication number: 20100190831
    Abstract: GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
    Type: Application
    Filed: December 17, 2009
    Publication date: July 29, 2010
    Inventors: Dong Fang Shi, Jiangao Song, Jingyuan Ma, Aaron Novack, Phuongly Pham, Imad Fayek Nashashibi, Christopher J. Rabbat, Xin Chen
  • Triazolyl phenyl benzenesulfonamides
    Patent number: 7718683
    Abstract: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
    Type: Grant
    Filed: July 10, 2007
    Date of Patent: May 18, 2010
    Assignee: ChemoCentryx, Inc.
    Inventors: Trevor T. Charvat, Cheng Hu, Anita Melikian, Aaron Novack, Andrew M. K. Pennell, Sreenivas Punna, Edward J. Sullivan, Xuefei Tan, William D. Thomas, Solomon Ungashe, Yibin Zeng
  • Substituted quinolones and methods of use
    Patent number: 7557213
    Abstract: Substituted quinolone compounds and compositions are provided along with methods for the use of those compounds in the treatment of diseases and disorders such as cancer.
    Type: Grant
    Filed: November 13, 2006
    Date of Patent: July 7, 2009
    Assignee: ChemoCentryx, Inc.
    Inventors: Anita Melikian, John Jessen Wright, Antoni Krasinski, Cheng Hu, Aaron Novack
  • N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS
    Publication number: 20090137590
    Abstract: Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control.
    Type: Application
    Filed: July 10, 2008
    Publication date: May 28, 2009
    Inventors: Jingyuan Ma, Christopher J. Rabbat, Jiangao Song, Xin Chen, Imad Nashashibi, Zuchun Zhao, Aaron Novack, Dong Fang Shi, Peng Cheng, Yan Zhu, Alison Murphy
  • N-(2-(HETARYL)ARYL) ARYLSULFONAMIDES AND N-(2-(HETARYL) HETARYL ARYLSULFONAMIDES
    Publication number: 20090005410
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: June 17, 2008
    Publication date: January 1, 2009
    Applicant: CHEMOCENTRYX, INC.
    Inventors: Trevor T. Charvat, Cheng Hu, Anita Melikian, Aaron Novack, Andrew M.K. Pennell, Edward J. Sullivan, William D. Thomas, Solomon Ungashe, Penglie Zhang, Jay Powers, Sreenivas Punna
  • TRIAZOLYL PHENYL BENZENESULFONAMIDES
    Publication number: 20080039465
    Abstract: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: July 10, 2007
    Publication date: February 14, 2008
    Inventors: Trevor Charvat, Cheng Hu, Anita Melikian, Aaron Novack, Andrew Pennell, Sreenivas Punna, Edward Sullivan, Xuefei Tan, William Thomas, Solomon Ungashe, Yibin Zeng
  • Substituted quinolones and methods of use
    Publication number: 20070167443
    Abstract: Substituted quinolone compounds and compositions are provided along with methods for the use of those compounds in the treatment of diseases and disorders such as cancer.
    Type: Application
    Filed: November 13, 2006
    Publication date: July 19, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: Anita Melikian, John Wright, Antoni Krasinski, Cheng Hu, Aaron Novack